Overview

The Gene Technology Act 2000 was enacted to regulate the use of genetically modified organisms (GMOs) in Australia, aiming to protect human health and safety and the environment by managing the risks associated with gene technology. The Act established the Office of the Gene Technology Regulator (OGTR) to oversee the regulation of GMOs, ensuring that any risks are identified and managed appropriately. This legislation was introduced to fill a gap in regulatory frameworks concerning the potential impacts of GMOs, providing a structured approach to assess and mitigate any risks. The Act was enacted by the Australian Parliament, reflecting the policy objective of maintaining a balanced approach that encourages innovation in biotechnology while safeguarding public and environmental health.

Scope and Application

The Genetically Modified Canola Field Trial, as outlined in C2013G01337, applies to entities such as Nuseed Pty Ltd, which has submitted Licence Application DIR 123 to the Gene Technology Regulator for the trial. The trial specifically pertains to genetically modified canola intended for altered oil content, with the application seeking approval for a controlled release in designated trial sites across New South Wales, Victoria, and Western Australia. The scope of the Act is geographically confined to these three states, and it is administered under the national framework established by Australia's gene technology regulatory system. This system is designed to safeguard human health and the environment by managing the risks associated with gene technology. The trial itself is intended to evaluate agronomic characteristics, oil content, and genetic stability of the GM canola, with strict conditions to limit potential risks. Although the GM canola will not enter the human food or animal feed supply, some GM material may be used in small-scale experimental animal feeding studies. The Act does not specify any exclusions or exemptions, and the application of the Act may be extended or restricted through subordinate instruments such as licence conditions formulated by the Regulator.

Key Provisions

The main operative sections of this legislation, specifically Licence Application DIR 123 from Nuseed Pty Ltd, concern the limited and controlled release of genetically modified (GM) canola for field trials. Section 35 of the Gene Technology Act 2004 (Cth) provides the framework for such applications, which must be submitted to the Gene Technology Regulator for assessment. The field trial in question, as outlined in section 36, is intended to evaluate the agronomic characteristics, oil content, and genetic stability of GM canola under field conditions. The trial is to take place between March 2014 and March 2019, with trial sites limited to 153 possible local government areas (LGAs) in New South Wales, Victoria, and Western Australia. The size of the trial sites will increase over the trial period, starting with a maximum of four sites of up to 2 hectares in 2014, six sites of up to 10 hectares in 2015, and ten sites of up to 20 hectares in each subsequent year. The Act imposes several obligations and requirements on Nuseed Pty Ltd and the Gene Technology Regulator. Section 35 requires that a detailed Risk Assessment and Risk Management Plan (RARMP) be prepared and submitted along with the licence application. This RARMP must evaluate the potential risks to human health and the environment and propose measures to mitigate those risks. Section 36 outlines the specific conditions that must be met for the trial, including limitations on the size, location, and duration of the release, as well as restrictions on the spread and persistence of the GMOs and introduced genetic material. Additionally, Nuseed Pty Ltd must ensure that the GM canola does not enter the human food or animal feed supply, although some GM material may be used for small-scale experimental animal feeding studies. Failure to comply with the requirements of the Gene Technology Act 2004 can result in various civil and criminal consequences. Under section 64 of the Act, any person who contravenes a condition of a licence or authorisation may be liable to a fine of up to $66,000 for individuals and $330,000 for bodies corporate. Furthermore, under section 65, any person who causes or permits a release of genetically modified organisms in contravention of the Act may be liable to a fine of up to $1.1 million for individuals and $5.5 million for bodies corporate. These penalties reflect the seriousness with which the Act treats breaches and the potential risks posed by unauthorised or non-compliant gene technology activities.